Cargando...
Potential options for managing LOX+ ER− breast cancer patients
Overexpression of lysyl oxidase (LOX) is often observed in estrogen receptor negative (ER–) breast cancer patients with bone metastasis. In the present bioinformatics study, we observed that LOX is a prognostic factor for poor progression free survival in patients with ER– breast cancer. LOX overexp...
Gardado en:
| Publicado en: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Impact Journals LLC
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5078060/ https://ncbi.nlm.nih.gov/pubmed/27147578 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9073 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|